巨大肝細胞癌に対し,TACE2回施行のみで完全奏効を得られた超高齢者の1例

• 資料種別: 記事
• タイトル: 巨大肝細胞癌に対し,TACE2回施行のみで完全奏効を得られた超高齢者の1例
• 著者・編者: 山口 教宗; 白木 孝之; 宮下 将太郎; 仁木 まい子; 早川 智彬; 田中 元樹; 清水 崇行; 松本 尊嗣; 森 昭三; 青木 琢
• 著者標目: 山口 教宗; 白木 孝之; 宮下 将太郎; 仁木 まい子; 早川 智彬; 田中 元樹; 清水 崇行; 松本 尊嗣; 森 昭三; 青木 琢
• 並列タイトル等: Complete Response to Transcatheter Arterial Chemoembolization in a Super Elderly Patient with Giant Hepatocellular Carcinoma : a Case Report
• タイトル（掲載誌）: 肝臓
• 巻号年月日等（掲載誌）: 67(1):2026.1
• 掲載巻: 67
• 掲載号: 1
• 掲載ページ: 43-50
• 掲載年月日（W3CDTF）: 2026-01
• ISSN（掲載誌）: 0451-4203
• ISSN-L（掲載誌）: 0451-4203
• 出版事項（掲載誌）: 東京 : 日本肝臓学会
• 出版地（国名コード）: JP
• 本文の言語コード: jpn
• 件名標目: 肝細胞癌; 経カテーテル的肝動脈化学塞栓療法; 完全奏効; 超高齢者; 巨大腫瘍; hepatocellular carcinoma; transcatheter arterial chemoembolization; complete response; elderly patient; giant tumor
• NDLC: ZS21
• 対象利用者: 一般
• 所蔵機関: 国立国会図書館
• 請求記号: Z19-130
• 連携機関・データベース: 国立国会図書館 : 国立国会図書館雑誌記事索引; https://ndlsearch.ndl.go.jp
• 書誌ID（NDLBibID）: 034546858; http://id.ndl.go.jp/bib/034546858
• 整理区分コード: 632

• 要約等: <p>We report a case of complete response (CR) to transcatheter arterial chemoembolization (TACE) in a male aged >90 years with giant hepatocellular carcinoma (HCC). The patient presented with a 15-cm tumor in the center of the liver. Despite poor prognostic factors, including large tumor size and markedly elevated AFP level (>99999 ng/mL), CR was achieved after only two TACE sessions using drug-eluting beads. The patient has remained on CR for 44 months without severe adverse events. This case suggests that TACE can be an effective treatment alternative for older adult patients with giant HCC when appropriate patient selection is made on the basis of factors, including single tumor, absence of vascular invasion, and preserved liver function.</p>; <p>90歳代前半男性の巨大肝細胞癌に対するTACEによる完全奏効例を報告する．肝中央に15 cm大の腫瘍を認め，腫瘍径および著明なAFP高値（＞99999 ng/mL）という予後不良因子を有していたにもかかわらず，DC-Beadを用いたTACE 2回施行のみで完全奏効（CR）が得られ，44カ月間のCR維持が可能であった．本症例は，単発，脈管侵襲なし，良好な肝予備能などの適切な症例選択により，超高齢者の巨大肝細胞癌に対してもTACEが有効な治療選択肢となり得ることを示唆している．</p>
• DOI: 10.2957/kanzo.67.43
• オンライン閲覧公開範囲: インターネット公開
• 連携機関・データベース: 科学技術振興機構 : J-STAGE; http://www.jstage.jst.go.jp

• 要約等: <p>90歳代前半男性の巨大肝細胞癌に対するTACEによる完全奏効例を報告する．肝中央に15 cm大の腫瘍を認め，腫瘍径および著明なAFP高値（＞99999 ng/mL）という予後不良因子を有していたにもかかわらず，DC-Beadを用いたTACE 2回施行のみで完全奏効（CR）が得られ，44カ月間のCR維持が可能であった．本症例は，単発，脈管侵襲なし，良好な肝予備能などの適切な症例選択により，超高齢者の巨大肝細胞癌に対してもTACEが有効な治療選択肢となり得ることを示唆している．</p>
• DOI: 10.2957/kanzo.67.43; https://doi.org/10.2957/kanzo.67.43
• 関連情報（URI）: http://id.ndl.go.jp/bib/034546858; https://ndlsearch.ndl.go.jp/books/R000000004-I034546858; https://www.jstage.jst.go.jp/article/kanzo/67/1/67_43/_pdf; https://search.jamas.or.jp/link/ui/2026134410
• 参照: Spontaneous regression of hepatocellular carcinoma: A mini-review; https://cir.nii.ac.jp/crid/1360002220760881792; RETRACTED: Clinical significance of the best response during repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma; https://cir.nii.ac.jp/crid/1360011146411336320; RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis; https://cir.nii.ac.jp/crid/1360021393304815744; Efficacy and Safety Analysis of Transarterial Chemoembolization Plus Donafenib With or Without Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Prospective, Single-Arm, Single-Center, Phase II Clinical Study; https://cir.nii.ac.jp/crid/1360025802214877056; Spontaneous Regression of Hepatocellular Carcinoma: When the Immune System Stands Up to Cancer; https://cir.nii.ac.jp/crid/1360025803328623616; Hepatocellular carcinoma; https://cir.nii.ac.jp/crid/1360292620030370688; Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation?; https://cir.nii.ac.jp/crid/1360298760629630720; Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602; https://cir.nii.ac.jp/crid/1360307280629022208; Rate and Predictive Factors for Sustained Complete Response after Selective Transarterial Chemoembolization (TACE) in Patients with Hepatocellular Carcinoma; https://cir.nii.ac.jp/crid/1360574093750851456; Proteoglycan-4 predicts good prognosis in patients with hepatocellular carcinoma receiving transcatheter arterial chemoembolization and inhibits cancer cell migration in vitro; https://cir.nii.ac.jp/crid/1360588755708113536; Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial; https://cir.nii.ac.jp/crid/1360855570236395648; New Data Supporting Modified RECIST (mRECIST) for Hepatocellular Carcinoma; https://cir.nii.ac.jp/crid/1360869860546756480; Transarterial Chemoembolization Combined With Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis; https://cir.nii.ac.jp/crid/1360870228965420928; Transarterial Chemoembolization Monotherapy Versus Combined Transarterial Chemoembolization–Microwave Ablation Therapy for Hepatocellular Carcinoma Tumors ≤5 cm: A Propensity Analysis at a Single Center; https://cir.nii.ac.jp/crid/1360870230943960064; Transarterial chemoembolization combined with sintilimab and lenvatinib for the treatment of unresectable hepatocellular carcinoma: a retrospective study; https://cir.nii.ac.jp/crid/1360870230994617600; Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT–pathologic correlation in 178 liver explants; https://cir.nii.ac.jp/crid/1362262945636142080; Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics; https://cir.nii.ac.jp/crid/1362825893943639936; Spontaneous regression of hepatocellular carcinoma is most often associated with tumour hypoxia or a systemic inflammatory response; https://cir.nii.ac.jp/crid/1363388845916329472; TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON; https://cir.nii.ac.jp/crid/1363388846191557632; Chemoembolization for hepatocellular carcinoma; https://cir.nii.ac.jp/crid/1363951795702874368; Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma; https://cir.nii.ac.jp/crid/1364233268317699328; Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma; https://cir.nii.ac.jp/crid/1364233269534290048
• 連携機関・データベース: 国立情報学研究所 : CiNii Research; https://cir.nii.ac.jp/
• 提供元機関・データベース: Japan Link Center; https://japanlinkcenter.org/top; 雑誌記事索引データベース; https://ndlsearch.ndl.go.jp; Crossref; https://www.crossref.org
• 書誌ID（NDLBibID）: 034546858; http://id.ndl.go.jp/bib/034546858